Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.77 |
| ▸ | MEN1 | O00255 | 1/20 | 0.77 |
| ▸ | ABL1 | P00519 | 1/20 | 0.77 |
| ▸ | LMNA | P02545 | 1/20 | 0.77 |
| ▸ | PKM | P14618 | 1/20 | 0.77 |
| ▸ | IDE | P14735 | 1/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.77 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.77 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.77 |
| ▸ | HLCS | P50747 | 6/20 | 0.70 |
| ▸ | CA12 | O43570 | 7/20 | 0.49 |
| ▸ | CA1 | P00915 | 7/20 | 0.49 |
| ▸ | CA2 | P00918 | 7/20 | 0.49 |
| ▸ | CA9 | Q16790 | 7/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Biotin SCHEMBL8672971 | 0.99 | TDP1 (0.76) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL6033491 | 0.94 | TDP1 (0.87) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL8651197 | 0.94 | TDP1 (0.87) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL770770 | 0.93 | TDP1 (0.85) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL3425472 | 0.93 | TDP1 (0.85) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL739967 | 0.93 | TDP1 (0.85) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL8672968 | 0.93 | TDP1 (0.85) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL987288 | 0.92 | TDP1 (0.79) | TDP1MEN1ABL1LMNAPKM | |
| Hexanoate SCHEMBL4243024 | 0.92 | TDP1 (0.79) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL16653090 | 0.92 | TDP1 (0.83) | TDP1MEN1ABL1LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4356927-A2 | ANTIBODY BASED REAGENTS THAT SPECIFICALLY RECOGNIZE TOXIC OLIGOMERIC FORMS OF TAU | Arizona Board of Regents on behalf of Arizona State University (US) | 2024-04-24 | — | — | EP | disclosed |
| EP-2906596-B1 | ANTIBODY BASED REAGENTS THAT SPECIFICALLY RECOGNIZE TOXIC OLIGOMERIC FORMS OF TAU | UNIV ARIZONA STATE (US) | 2023-12-27 | — | — | EP | disclosed |
| WO-2023044400-A1 | BI-FUNCTIONAL JANUS REPORTER PARTICLE AND METHODS FOR MAKING AND USING THE SAME | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2023-03-23 | — | — | WO | disclosed |
| US-11168321-B2 | Methods of creating and screening DNA-encoded libraries | X-CHEM, INC. (US) | 2021-11-09 | — | — | US | disclosed |
| US-20210324060-A1 | ANTIBODY BASED REAGENTS THAT SPECIFICALLY RECOGNIZE TOXIC OLIGOMERIC FORMS OF TAU | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2021-10-21 | — | — | US | disclosed |
| CN-107916456-B | Method for generating and screening libraries encoded by DNA | X-化学有限公司 | 2021-08-10 | — | — | CN | disclosed |
| US-11046755-B2 | Antibody based reagents that specifically recognize toxic oligomeric forms of tau | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2021-06-29 | — | — | US | disclosed |
| US-20200385709-A1 | METHODS OF CREATING AND SCREENING DNA-ENCODED LIBRARIES | X-CHEM, INC. | 2020-12-10 | — | — | US | disclosed |
| EP-3211126-B1 | METHODS OF CREATING AND SCREENING DNA-ENCODED LIBRARIES | X CHEM INC (US) | 2020-10-21 | — | — | EP | disclosed |
| US-20200299367-A1 | ANTIBODY BASED REAGENTS THAT SPECIFICALLY RECOGNIZE TOXIC OLIGOMERIC FORMS OF TAU | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2020-09-24 | — | — | US | disclosed |
| WO-2007051032-A2 | CHEMICAL DERIVATIZATION, DETECTION, AND IDENTIFICATION OF PEPTIDE AND PROTEIN MODIFICATIONS | INTEL CORPORATION (US) | 2007-05-03 | — | — | WO | disclosed |
| US-20070099256-A1 | Chemical derivatization, detection, and identification of peptide and protein modifications | Apricot Ideas, Inc. | 2007-05-03 | — | — | US | disclosed |
| US-20070059771-A1 | Detecting and modulating post-translational O-sulfonation of serine and threonine residues on polypeptides | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-03-15 | — | — | US | disclosed |
| US-7138228-B2 | Protein O-sulfonation | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-11-21 | — | — | US | disclosed |
| US-20050095647-A1 | Enrichment and tagging of glycosylated proteins | AGILENT TECHNOLOGIES, INC. | 2005-05-05 | — | — | US | disclosed |
| WO-2005026321-A2 | PROTEIN O-SULFONATION | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE (US) | 2005-03-24 | — | — | WO | disclosed |
| US-20050054020-A1 | Protein O-sulfonation | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2005-03-10 | — | — | US | disclosed |
| US-6534035-B1 | In vivo imaging localization using labeled alpha-2 antiplasmin polypeptide | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2003-03-18 | — | — | US | disclosed |
| EP-1079866-A2 | METHODS OF INHIBITING CLOT FORMATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2001-03-07 | — | — | EP | disclosed |
| WO-1999061072-A2 | METHODS OF INHIBITING CLOT FORMATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1999-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11168321-B2 | Methods of creating and screening DNA-encoded libraries | PCNA, DNA2, POLM | TDP1 129/4885MEN1 1399/4885ABL1 2359/4885 |
| US-20200385709-A1 | METHODS OF CREATING AND SCREENING DNA-ENCODED LIBRARIES | PCNA, DNA2, POLM | TDP1 129/4885MEN1 1399/4885ABL1 2359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.